--- title: "YK-11: Dosing & Vendor Prices — BodyHackGuide" description: "YK-11: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "YK-11" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "YK-11", "description": "YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075).", "url": "https://www.bodyhackguide.co/compound/yk-11", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "79.99", "highPrice": "84.99", "priceCurrency": "USD", "offerCount": "2", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "79.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/yk11capsulated/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } }, { "@type": "Offer", "price": "84.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/yk-11/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "YK-11 500mg liquid" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "YK-11", "description": "YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075).", "lastReviewed": "2026-09-07T04:47:52.299Z", "url": "https://www.bodyhackguide.co/compound/yk-11", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "YK-11", "alternateName": [ "YK11", "YK 11", "Myostine", "Steroidal SARM YK-11" ], "description": "YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075).", "activeIngredient": "YK-11", "administrationRoute": "Oral", "mechanismOfAction": "YK-11 is a steroidal partial agonist of the androgen receptor. It binds the receptor and drives nuclear translocation, but does not induce the amino-terminal to carboxy-terminal interaction that full androgen agonists cause, which is thought to explain its partial and gene-selective activity in an androgen response element reporter assay and in androgen receptor positive human breast cancer cells (PMID: 21372378). Follow-up work attributes the gene selectivity to differences in DNA binding and co-regulator recruitment relative to dihydrotestosterone (PMID: 36030969). The separate myostatin claim traces to a single cell study in which YK-11 induced follistatin expression in mouse C2C12 myoblasts and the differentiation effect was blocked by an anti-follistatin antibody (PMID: 23995658). No direct inhibition of myostatin by YK-11 has been shown.", "dosageForm": "capsule, liquid", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is YK-11 used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075)." } }, { "@type": "Question", "name": "What forms does YK-11 come in?", "acceptedAnswer": { "@type": "Answer", "text": "YK-11 is available in capsule, liquid forms." } }, { "@type": "Question", "name": "How much does YK-11 cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $79.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare YK-11 vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fyk-11) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. YK-11 ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Best price right now $0.17/mg · $84.99 for 500mg at Disguised Alpha [Buy at Disguised Alpha](https://www.bodyhackguide.co/go/disguised-alpha?utm_source=compound-sticky-bar&utm_campaign=d740653c-82ad-4a8e-8a0d-a44f4a35259e&utm_medium=best-price-cta) [Where to buy YK-11](/buy/yk-11) [YK-11 coupon codes](/coupons/yk-11) [YK-11 protocol](/protocol/yk-11) [Alternatives to YK-11](/alternatives-to/yk-11) [YK-11 side effects](/side-effects/yk-11) 1. [Home](/) 3. [Compounds](/compare) 5. YK-11 ![YK-11 molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # YK-11 Performance Preclinical Download PDF Also known as: YK11, YK 11, Myostine, Steroidal SARM YK-11 YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-\[(1-methoxyethylidene)bis(oxy)\]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. Half-Life: Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415) Route: Oral MW: 430.5 g/mol CAS: 1370003-76-1 Last reviewed: Sep 7, 2026 [ Performance Category ](/wiki#cat-performance) Preclinical Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices2 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $79.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/yk11capsulated/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism YK-11 is a steroidal partial agonist of the androgen receptor. It binds the receptor and drives nuclear translocation, but does not induce the amino-terminal to carboxy-terminal interaction that full androgen agonists cause, which is thought to explain its partial and gene-select… Half-Life Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415) Routes Oral Potential Benefits Induced myogenic differentiation and follistatin expression in mouse C2C12 myoblast cells, reversed by an anti-follistatin antibody (PMID: 23995658) Increased proliferation and mineralization and raised osteoblast differentiation markers in mouse MC3T3-E1 osteoblast cells (PMID: 29491216) Promoted osteogenic differentiation of rat bone marrow stromal cells and improved repair of cranial bone defects in rats (PMID: 39660819) Reduced pro-inflammatory cytokines, organ damage markers and mortality in mice with gram-negative bacterial sepsis (PMID: 33588136) ### Overview YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-\[(1-methoxyethylidene)bis(oxy)\]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075). ### Potential Research Fields Androgen receptor pharmacology Myostatin and follistatin signaling Sports drug testing Neurotoxicology ## Chemical Information IUPAC Name Not yet available CAS Number 1370003-76-1 Molecular Formula C25H34O6 Molecular Mass 430.5 g/mol ![YK-11 molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/119058028/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/119058028) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications No sourced clinical contraindications exist because there are no human studies. Mechanism-based: as an androgen receptor agonist it should be avoided in pregnancy because of the risk of virilizing a female fetus, and in anyone with known or suspected prostate cancer. The rat neurotoxicity findings are a mechanism-based reason for caution in general (PMID: 37468001, PMID: 38521455). Athletes in tested sport must avoid it, since it is prohibited at all times (PMID: 28137616). Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $79.99 up to $84.99 Best $/mg $0.1700 Vendors 1 Listings 2 capsule, liquid [Sign in for alerts ](/auth) Form Allcapsuleliquid Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK YK-11 capsules (60) capsule 60 capsules ● In Stock $79.99 BEST — — [Buy](https://disguisedalpha.com/product/yk11capsulated/?coupon=reddit) ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK YK-11 50 mg/mL, 10 mL liquid 10 mL (50 mg/mL) ● In Stock $84.99 VALUE $0.170 — [Buy](https://disguisedalpha.com/product/yk-11/?coupon=reddit) Get YK-11 Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $79.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with YK-11. [Sign in](/auth) Current low $79.99 as of Sep 7, 2026 7-day low $79.99 30-day low $79.99 30-day change — baseline building Tracking since Sep 7, 2026 · 2 data points ### Vendors Selling YK-11 [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 2 listings · from $79.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### ITPP Performance Preclinical ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues. Research compound — IV infusion in studies, no established oral doses 36 studies View Profile ](/compound/itpp)[ ### LGD-4033 (Ligandrol) Performance Phase 2 LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095). t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616) Preclinical View Profile ](/compound/lgd-4033)[ ### Ostarine (Enobosarm, MK-2866) Performance Phase 3 Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. t½ Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861) Preclinical View Profile ](/compound/ostarine)[ ### PEG-MGF Performance Preclinical PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 Preclinical View Profile ](/compound/peg-mgf)[ ### RAD-140 (Testolone) Performance Phase 1 RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). t½ Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686) Preclinical View Profile ](/compound/rad-140)[ ### SLU-PP-332 Performance Preclinical SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism. Research compound — no established human doses. Animal studies: 10-50 mg/kg 8 studies View Profile ](/compound/slu-pp-332) [ View Full Dosage Guide → Protocols, calculator & safety for YK-11 ](/guides/dosage/yk-11) ### Related Articles [All Posts](/blog) [ #### Myostatin: The Muscle Brake, the Inhibitors, and What Actually Works (2026) Myostatin is your body's brake on muscle growth. The famous mutations, the inhibitor drugs (apitegromab, bimagrumab) and their honest trial record, the supplement hype, and how to keep muscle on a GLP-1. 7/9/2026 ](/blog/myostatin-and-muscle) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $79.99 [Buy Now](https://disguisedalpha.com/product/yk11capsulated/?coupon=reddit) 1 vendors · 2 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415) Molecular Weight 430.5 g/mol Administration Oral CAS Number 1370003-76-1 Trial Phase Preclinical 0 [Full Dosage Guide](/guides/dosage/yk-11)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is YK-11 used for in research? YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-\[(1-methoxyethylidene)bis(oxy)\]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075). What forms does YK-11 come in? YK-11 is available in capsule, liquid forms. How much does YK-11 cost? Prices start at $79.99 across 1 verified vendor. How do I compare YK-11 vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### ITPP Performance Preclinical ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues. Research compound — IV infusion in studies, no established oral doses 36 studies View Profile ](/compound/itpp)[ ### LGD-4033 (Ligandrol) Performance Phase 2 LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095). t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616) Preclinical View Profile ](/compound/lgd-4033)[ ### Ostarine (Enobosarm, MK-2866) Performance Phase 3 Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. t½ Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861) Preclinical View Profile ](/compound/ostarine)[ ### PEG-MGF Performance Preclinical PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 Preclinical View Profile ](/compound/peg-mgf)[ ### RAD-140 (Testolone) Performance Phase 1 RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). t½ Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686) Preclinical View Profile ](/compound/rad-140)[ ### SLU-PP-332 Performance Preclinical SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism. Research compound — no established human doses. Animal studies: 10-50 mg/kg 8 studies View Profile ](/compound/slu-pp-332) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-yk-11) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋